ResMed
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ResMed and other ETFs, options, and stocks.About RMD
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases.
RMD Key Statistics
Stock Snapshot
As of today, ResMed(RMD) shares are valued at $247.84. The company's market cap stands at 36.47B, with a P/E ratio of 25.10 and a dividend yield of 89.3%.
On 2025-11-07, ResMed(RMD) stock moved within a range of $242.02 to $250.70. With shares now at $247.84, the stock is trading +2.4% above its intraday low and -1.1% below the session's peak.
Trading activity shows a volume of 2.23M, compared to an average daily volume of 1.55M.
The stock's 52-week range extends from a low of $199.92 to a high of $293.81.
The stock's 52-week range extends from a low of $199.92 to a high of $293.81.
RMD News
ResMed (RMD) has caught investor attention following its Q1 results, which showed steady growth in both revenue and net income. The stock pulled back slightly,...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Baird lowered the firm’s price target on ResMed (RMD) to $300 from $320 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q3 res...
Analyst ratings
69%
of 29 ratingsMore RMD News
ResMed (RMD) posted impressive numbers with net profit margins climbing to 27.4% from 23.1% a year ago, and EPS advancing 29.2% year-over-year. Over the last fi...
Fintel reports that on October 31, 2025, Mizuho maintained coverage of ResMed (NYSE:RMD) with a Outperform recommendation. Analyst Price Forecast Suggests 21.9...
ResMed Inc. recently reported first quarter 2026 earnings, posting sales of US$1.34 billion and net income of US$348.54 million, both higher than the same perio...
ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday. The company posted quarterly earnings of $2.55 per share which...
Analyst David Bailey of Morgan Stanley maintained a Buy rating on Resmed, boosting the price target to $305.00. Elevate Your Investing Strategy: Take advantage...